Ras and Sars-Cov-2 Interaction: Short Review of the Latest Evidence
Russian Journal of Infection and Immunity
; 13(1):171-173, 2023.
Article
in English
| EMBASE | ID: covidwho-2320208
ABSTRACT
Coronavirus SARS-CoV-2 is responsible for the coronavirus disease (COVID-19) cause of the recent global pandemic, which is causing thousands of deaths worldwide and represents a health challenge with few precedents in human history. The angiotensin 2 conversion enzyme (ACE-2) has been identified as the receptor that facilitates access to SARSCoV-2 in cells;evidence shows that its concentration varies during the various stages of viral infection. Therapeutic agents modifying the renin-angiotensin system (RAS) may be able to modulate the concentration of ACE-2 and the various components of the system. In this article we examine the latest evidence on the association between the use of RAS modifying agents and coronavirus 2019 (COVID-19) disease caused by SARS-CoV-2. Our investigation and critical literature research does not suggest discontinuation of ACEIs/ARBs treatment in clinical practice as there is a lack of robust evidence. However, we recommend further well-structured epidemiological studies investigating this sensitive issue that may provide important new suggestions for implementing guidelines.Copyright © Vitiello A., Ferrara F., 2023.
covid-19; pandemic; renin-angiotensin system; SARS-CoV-2; article; blood pressure; coronavirus disease 2019; electronic health record; human; plasma renin activity; renin angiotensin aldosterone system; Severe acute respiratory syndrome coronavirus 2; angiotensin I; angiotensin II; angiotensin receptor antagonist; renin inhibitor
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Language:
English
Journal:
Russian Journal of Infection and Immunity
Year:
2023
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS